Basic Information
| LncRNA/CircRNA Name | FBXL19-AS1 |
| Synonyms | NA |
| Region | GRCh38_16:30919319-30923269 |
| Ensemble | ENSG00000260852 |
| Refseq | NR_024348 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | OS tumor tissues, human OS cell lines MG63, U2OS, SAOS2, HOS, 143B, and the normal osteoblast cell line hFOB1.19 |
| Expression Pattern | up-regulated |
| Function Description | lncRNA FBXL19-AS1 was upregulated in OS tissues and cell lines. In vitro experiments showed that FBXL19-AS1 promoted OS cell proliferation, migration, and invasion. Inhibiting miR-346 led to a significant upregulation of FBXL19-AS1, suggesting FBXL19-AS1 was negatively regulated by miR-346, which was further confirmed by the inverse correlation between FBXL19-AS1 and miR-346 expression in OS patient specimens. Furthermore, we proved that miR-346 could directly target FBXL19-AS1 through luciferase assays, suggesting FBXL19-AS1 could sponge miR-346. Additionally, inhibiting miR-346 blocked the effects of silencing FBXL19-AS1 on proliferation, migration, and invasion. Moreover, inhibiting FBXL19-AS1 significantly promoted the malignancy of MG63 and 143B cells in vivo. |
| Pubmed ID | 30555237 |
| Year | 2018 |
| Title | lncRNA FBXL19-AS1 Regulates Osteosarcoma Cell Proliferation, Migration and Invasion by Sponging miR-346 |
External Links
| Links for FBXL19-AS1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |